vs
CALAVO GROWERS INC（CVGW）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CALAVO GROWERS INC的1.0倍（$127.1M vs $124.7M），再鼎医药同比增速更快（17.1% vs -26.6%），CALAVO GROWERS INC自由现金流更多（$1.2M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -1.2%）
卡拉沃种植者公司是一家国际化农产消费品企业，核心业务涉及牛油果及其他鲜果、新鲜预制食品的包装与分销，产品面向全球各地的餐饮门店、零售卖场以及个人客户供应，是生鲜果蔬领域颇具规模的供应商。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CVGW vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.0倍
$124.7M
营收增速更快
ZLAB
高出43.8%
-26.6%
自由现金流更多
CVGW
多$27.9M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $124.7M | $127.1M |
| 净利润 | $3.8M | — |
| 毛利率 | 9.3% | 51.0% |
| 营业利润率 | -1.4% | -54.6% |
| 净利率 | 3.1% | — |
| 营收同比 | -26.6% | 17.1% |
| 净利润同比 | 2846.0% | — |
| 每股收益（稀释后） | $0.22 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CVGWZLAB
| Q4 25 | $124.7M | $127.1M | ||
| Q3 25 | $178.8M | $115.4M | ||
| Q2 25 | $190.5M | $109.1M | ||
| Q1 25 | $154.4M | $105.7M | ||
| Q4 24 | $170.0M | $108.5M | ||
| Q3 24 | $179.6M | $101.8M | ||
| Q2 24 | $184.4M | $100.1M | ||
| Q1 24 | $127.6M | $87.1M |
净利润CVGWZLAB
| Q4 25 | $3.8M | — | ||
| Q3 25 | $4.7M | $-36.0M | ||
| Q2 25 | $6.8M | $-40.7M | ||
| Q1 25 | $4.4M | $-48.4M | ||
| Q4 24 | $-139.0K | — | ||
| Q3 24 | $-732.0K | $-41.7M | ||
| Q2 24 | $6.1M | $-80.3M | ||
| Q1 24 | $-6.3M | $-53.5M |
毛利率CVGWZLAB
| Q4 25 | 9.3% | 51.0% | ||
| Q3 25 | 10.2% | 59.5% | ||
| Q2 25 | 9.5% | 60.6% | ||
| Q1 25 | 10.2% | 63.6% | ||
| Q4 24 | 9.7% | 61.5% | ||
| Q3 24 | 11.2% | 64.1% | ||
| Q2 24 | 11.1% | 64.9% | ||
| Q1 24 | 8.4% | 61.4% |
营业利润率CVGWZLAB
| Q4 25 | -1.4% | -54.6% | ||
| Q3 25 | 4.8% | -42.3% | ||
| Q2 25 | 4.0% | -50.3% | ||
| Q1 25 | 3.3% | -53.3% | ||
| Q4 24 | 1.8% | -62.6% | ||
| Q3 24 | 5.2% | -66.6% | ||
| Q2 24 | 4.0% | -76.0% | ||
| Q1 24 | -2.4% | -80.7% |
净利率CVGWZLAB
| Q4 25 | 3.1% | — | ||
| Q3 25 | 2.6% | -31.2% | ||
| Q2 25 | 3.6% | -37.3% | ||
| Q1 25 | 2.9% | -45.8% | ||
| Q4 24 | -0.1% | — | ||
| Q3 24 | -0.4% | -40.9% | ||
| Q2 24 | 3.3% | -80.2% | ||
| Q1 24 | -4.9% | -61.4% |
每股收益（稀释后）CVGWZLAB
| Q4 25 | $0.22 | $-0.05 | ||
| Q3 25 | $0.26 | $-0.03 | ||
| Q2 25 | $0.38 | $-0.04 | ||
| Q1 25 | $0.25 | $-0.04 | ||
| Q4 24 | $-0.01 | $-0.09 | ||
| Q3 24 | $-0.04 | $-0.04 | ||
| Q2 24 | $0.34 | $-0.08 | ||
| Q1 24 | $-0.35 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $61.2M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $206.9M | $715.5M |
| 总资产 | $292.2M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CVGWZLAB
| Q4 25 | $61.2M | $689.6M | ||
| Q3 25 | $63.8M | $717.2M | ||
| Q2 25 | $60.4M | $732.2M | ||
| Q1 25 | $48.5M | $757.3M | ||
| Q4 24 | $57.0M | $779.7M | ||
| Q3 24 | $1.1M | $616.1M | ||
| Q2 24 | $4.3M | $630.0M | ||
| Q1 24 | $5.7M | $650.8M |
股东权益CVGWZLAB
| Q4 25 | $206.9M | $715.5M | ||
| Q3 25 | $206.4M | $759.9M | ||
| Q2 25 | $206.6M | $791.7M | ||
| Q1 25 | $202.9M | $810.8M | ||
| Q4 24 | $200.3M | $840.9M | ||
| Q3 24 | $205.2M | $667.7M | ||
| Q2 24 | $207.3M | $704.2M | ||
| Q1 24 | $202.5M | $762.2M |
总资产CVGWZLAB
| Q4 25 | $292.2M | $1.2B | ||
| Q3 25 | $301.2M | $1.2B | ||
| Q2 25 | $321.5M | $1.2B | ||
| Q1 25 | $298.9M | $1.2B | ||
| Q4 24 | $301.1M | $1.2B | ||
| Q3 24 | $382.4M | $985.3M | ||
| Q2 24 | $411.4M | $987.4M | ||
| Q1 24 | $394.7M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $1.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | 1.0% | -21.0% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.60× | — |
| 过去12个月自由现金流最近4个季度 | $19.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CVGWZLAB
| Q4 25 | $2.3M | $-26.0M | ||
| Q3 25 | $8.0M | $-32.0M | ||
| Q2 25 | $15.7M | $-31.0M | ||
| Q1 25 | $-4.4M | $-61.7M | ||
| Q4 24 | $10.8M | $-55.8M | ||
| Q3 24 | $11.4M | $-26.8M | ||
| Q2 24 | $2.1M | $-42.2M | ||
| Q1 24 | $58.0K | $-90.1M |
自由现金流CVGWZLAB
| Q4 25 | $1.2M | $-26.7M | ||
| Q3 25 | $7.3M | $-35.0M | ||
| Q2 25 | $15.6M | $-33.9M | ||
| Q1 25 | $-4.7M | $-63.2M | ||
| Q4 24 | $10.5M | $-58.4M | ||
| Q3 24 | $11.3M | $-28.2M | ||
| Q2 24 | $745.0K | $-42.9M | ||
| Q1 24 | $-972.0K | $-91.1M |
自由现金流率CVGWZLAB
| Q4 25 | 1.0% | -21.0% | ||
| Q3 25 | 4.1% | -30.4% | ||
| Q2 25 | 8.2% | -31.1% | ||
| Q1 25 | -3.1% | -59.9% | ||
| Q4 24 | 6.2% | -53.8% | ||
| Q3 24 | 6.3% | -27.7% | ||
| Q2 24 | 0.4% | -42.9% | ||
| Q1 24 | -0.8% | -104.5% |
资本支出强度CVGWZLAB
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.2% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 0.8% | 1.1% |
现金转化率CVGWZLAB
| Q4 25 | 0.60× | — | ||
| Q3 25 | 1.69× | — | ||
| Q2 25 | 2.29× | — | ||
| Q1 25 | -1.00× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVGW
| Fresh Products | $104.7M | 84% |
| Segment Prepared | $14.5M | 12% |
| Tomatoes | $4.6M | 4% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
